Atrium Therapeutics Share Price Today

Atrium Therapeutics Q3FY26 Results: Net loss widens to $4.3 million

Net loss widened to $4.3 million in Q3FY26 from $0.04 million in Q3FY25. Pro-forma cash balance stands at $293.6 million, extending runway through 2028. Collaboration revenue grew to $15.3 million, driven by a $15.0 million BMS milestone. First patient dosed in Phase 1/2 Corventis trial for ATR 1072 in PRKAG2 syndrome.

Atrium Therapeutics grants inducement awards to new hire

Atrium Therapeutics granted inducement awards to one new non-executive employee on October 20, 2026. The package includes 9,500 stock options at $7.98 and 4,750 restricted stock units. Options vest over four years with monthly installments after the first year; RSUs vest annually. Grants were approved by independent directors under Nasdaq Listing Rule 5635(c)(4).

Yakira urges Atrium to launch strategic review after dilutive $50m raise

Atrium Therapeutics raised $50 million via private placement at ~$7.93 per share, a 44% discount from prior levels. Yakira Capital estimates net cash at $254 million ($14.85/share), meaning stock trades below cash value. Activist demands strategic review, citing BMS collaboration with up to $1.35 billion in R&D milestones. Board criticized for dilutive financing instead of rights offering, with proof of concept not expected until H2 2027.

Atrium Therapeutics secures $50 million in private placement

Atrium Therapeutics raises approximately $50 million in gross proceeds via private placement. Shares issued at $7.93 per unit alongside pre-funded warrants at $7.929. Proceeds will fund lead product development and extend cash runway through 2028. Investors include Sirenia Capital Management LP, Aberdeen Investments, and Casdin Capital.

Atrium Therapeutics grants 16,500 shares to new hire under Nasdaq rule

Atrium Therapeutics awarded 11,000 stock options and 5,500 RSUs to a new non-executive hire. Stock options have an exercise price of $13.48 per share, matching the grant date closing price. Both instruments vest 25% after one year, with remaining portions vesting over three years. Grants were approved by the independent Human Capital Management Committee under Nasdaq Rule 5635(c)(4).

Atrium launches $10 trillion CRE credit platform, maps $1.3 trillion data center debt

Atrium introduced a credit intelligence platform for the $10 trillion U.S. CRE market, unifying 150+ data sources. Its accompanying report maps $1.3 trillion in data center debt, noting $128 billion maturing through 2027 at lower rates and a shift toward private credit financing.